Breaking News, Financial News

Financial Report: WuXi PharmaTech

Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 4Q Revenues: $88.6 million (+20%) 4Q Earnings: $17.3 million (+42%) FY Revenues: $334.1 million (+24%) FY Earnings: $90.8 million (+72%) Comments: Growth in the quarter was driven by Lab Services revenue (+16%) and a 59% increase in Manufacturing Services revenues. For the year, growth was driven by both China- and U.S.-based Lab Services revenue (+18%) and 95% growth in Manufacturing Services revenues. In the quarter, earnings include a 38% growth in income from c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters